1. Scrip
  2. >>Business

Finance Watch: Many Mega-Rounds, Some Smaller VC Deals, But Few In The Middle

$100m-Plus Financings Leave Little For Mid-Sized Rounds

 
• By Mandy Jackson

Private Company Edition: June’s eight $100m-plus venture capital rounds already outpace the seven each raised in March, April and May, including €255m ($274.2m) for ITM and $200m for Upstream, but while there were five $25m or less VC financings during the past week, mid-sized deals were lacking.

Finance Watch Private Company
• Source: Shutterstock

The volume of $100m-plus venture capital mega-rounds continues to build throughout 2023 after a slow start, but a wider look at the biopharmaceutical VC landscape illustrates the valley of death that has emerged as venture capital investors exercise discretion.

There were eight mega-rounds announced between 5 and 12 June, including £96m ($120m) in initial funding for Beacon Therapeutics Holdings Limited on 12 June. That makes nine so far this month after Eikon Therapeutics, Inc. revealed the first $106m tranche of a series C round on 1 June, with seven in May, including a $150m series E round for Carmot Therapeutics Inc. on 25 May. (Also see "Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs" - Scrip, 2 June, 2023

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.